Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation

The Lancet Oncology

Volumn 14, Issue 2, 2013, Pages 159-167

  Kapur, Payal ^a   Peña Llopis, Samuel ^a,b,c   Christie, Alana ^c   Zhrebker, Leah ^a   Pavía Jiménez, Andrea ^a,b,c   Rathmell, W Kimryn ^d   Xie, Xian Jin ^c   Brugarolas, James ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BAP1 GENE; CANCER GRADING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUTANT; NEPHRECTOMY; OVERALL SURVIVAL; PBRM1 GENE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; MUTATION; NUCLEAR PROTEINS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84873081430     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70584-3     Document Type: Article

References (33)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005, 173:1853-1862.
3. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the Ssign Score. J Urol 2002, 168:2395-2400.
4. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649-1657.
5. Karakiewicz PI, Briganti A, Chun FK-H, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007, 25:1316-1322.
6. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63-67.
7. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530-2540.
8. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
9. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726-4734.
10. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011, 469:539-542.
11. van Haaften G, Dalgliesh GL, Davies H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009, 41:521-523.
12. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463:360-363.
13. Peña-Llopis S, Vega-Rubén-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012, 44:751-759.
14. Eble JN, Sauter G, Epstein JI Pathology and genetics of tumours of the urinary system and male genital organs 2004, IARC Press, Lyon, France.
15. Fuhrman SA, Lasky LC, Limas C Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
16. Edge SB, Byrd DR, Carducci MA AJCC cancer staging manual 2010, Springer, New York, NY. 7th edn.
17. Benjamini Y, Hochberg Y Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289-300.
18. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005, 104:511-520.
19. Tickoo SK, Gopalan A Pathologic features of renal cortical tumors. Urol Clin North Am 2008, 35:551-561.
20. Delahunt B, Sika-Paotonu D, Bethwaite PB, et al. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence. Am J Surg Pathol 2011, 35:1134-1139.
21. Brugarolas J Research translation and personalized medicine. Renal cell carcinoma 2012, 161-191. Springer, US. R.A. Figlin, W.K. Rathmell, B.I. Rini (Eds.).
22. Zhang H, Stallock JP, Ng JC, Reinhard C, Neufeld TP Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev 2000, 14:2712-2724.
23. Tsang CK, Bertram PG, Ai W, Drenan R, Zheng XF Chromatin-mediated regulation of nucleolar structure and RNA Pol I localization by TOR. EMBO J 2003, 22:6045-6056.
24. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007, 109:2257-2267.
25. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
26. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468.
27. Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A, Moch H VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 2010, 34:806-815.
28. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009, 69:4674-4681.
29. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
30. Sivanand S, Peña-Llopis S, Zhao H, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012, 4:137ra75.
31. Ruan HB, Han X, Li MD, et al. O-GlcNAc transferase/host cell factor C1 complex regulates gluconeogenesis by modulating PGC-1alpha stability. Cell Metab 2012, 16:226-237.
32. Guo G, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012, 44:17-19.
33. Brannon AR, Reddy A, Seiler M, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010, 1:152-163.